DE69712085T2 - Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle - Google Patents
Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalleInfo
- Publication number
- DE69712085T2 DE69712085T2 DE69712085T DE69712085T DE69712085T2 DE 69712085 T2 DE69712085 T2 DE 69712085T2 DE 69712085 T DE69712085 T DE 69712085T DE 69712085 T DE69712085 T DE 69712085T DE 69712085 T2 DE69712085 T2 DE 69712085T2
- Authority
- DE
- Germany
- Prior art keywords
- polypeptide
- hcv
- ns4a
- complex
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Metallurgy (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2527496P | 1996-09-12 | 1996-09-12 | |
| US08/731,336 US6153579A (en) | 1996-09-12 | 1996-10-18 | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
| PCT/US1997/016182 WO1998011134A1 (en) | 1996-09-12 | 1997-09-12 | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69712085D1 DE69712085D1 (de) | 2002-05-23 |
| DE69712085T2 true DE69712085T2 (de) | 2002-11-28 |
Family
ID=26699520
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69712085T Expired - Lifetime DE69712085T2 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare zusammensetzungen, die einen komplex von protein-domäne ns3aus dem virus von hepatitis c und ns4a enthalten und damit bereitgestellte kristalle |
| DE69736995T Expired - Lifetime DE69736995T2 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle |
| DE69723485T Expired - Lifetime DE69723485T2 (de) | 1996-09-12 | 1997-09-12 | Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69736995T Expired - Lifetime DE69736995T2 (de) | 1996-09-12 | 1997-09-12 | Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle |
| DE69723485T Expired - Lifetime DE69723485T2 (de) | 1996-09-12 | 1997-09-12 | Verfahren zur Identifizierung von Wirkstoffen gegen HCV durch Verwendung von Strukturkoordinaten der Hepatitis-C-Virus-Protease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6153579A (enExample) |
| EP (1) | EP0935609B1 (enExample) |
| JP (1) | JP2001501602A (enExample) |
| AT (3) | ATE244729T1 (enExample) |
| AU (1) | AU736857B2 (enExample) |
| CA (1) | CA2264964A1 (enExample) |
| DE (3) | DE69712085T2 (enExample) |
| DK (1) | DK0935609T3 (enExample) |
| ES (2) | ES2202228T3 (enExample) |
| IL (1) | IL128826A0 (enExample) |
| PT (2) | PT1118619E (enExample) |
| WO (1) | WO1998011134A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ335276A (en) | 1996-10-18 | 2000-09-29 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease |
| IL143798A0 (en) | 1999-01-08 | 2002-04-21 | Bristol Myers Squibb Co | Hepatitis c virus ns3 protease |
| US6524589B1 (en) * | 1999-04-08 | 2003-02-25 | Schering Corporation | Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same |
| JP2003511467A (ja) | 1999-10-14 | 2003-03-25 | ブリストル−マイヤーズ スクイブ カンパニー | アンドロゲンレセプターリガンド結合ドメインの結晶構造 |
| US7491808B2 (en) | 2000-06-15 | 2009-02-17 | Novartis Vaccines And Diagnostics, Inc. | HCV non-structural protein mutants and uses thereof |
| HUP0303172A3 (en) | 2000-06-28 | 2006-05-29 | Bristol Myers Squibb Co | Selective androgen receptor modulators and methods for their identification, desing and use |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1334179A2 (en) | 2000-11-14 | 2003-08-13 | Bristol-Myers Squibb Company | A human serpin secreted from lymphoid cells lsi-01 |
| CA2443393A1 (en) | 2001-04-03 | 2002-11-07 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof |
| US20030027315A1 (en) * | 2001-09-24 | 2003-02-06 | Ada Yonath | Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals |
| US20050009877A1 (en) * | 2003-05-15 | 2005-01-13 | Henry Lu | Methods of identifying HCV NS5B polymerase inhibitors and their uses |
| MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| ES2389201T3 (es) | 2003-10-27 | 2012-10-24 | Vertex Pharmaceuticals Incorporated | Mutantes de resistencia de la proteasa NS3/4A de HCV |
| WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
| US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
| NZ568324A (en) | 2005-11-11 | 2012-01-12 | Vertex Pharma | Hepatitis C virus variants |
| EP1991229A2 (en) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| JP2009531315A (ja) * | 2006-03-16 | 2009-09-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | 重水素化ｃ型肝炎プロテアーゼインヒビター |
| US8440443B1 (en) | 2006-05-16 | 2013-05-14 | Merck Sharp & Dohme Corp. | MEK1 polypeptides |
| EA200970806A1 (ru) | 2007-02-27 | 2010-08-30 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| US8575208B2 (en) | 2007-02-27 | 2013-11-05 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
| EP2436682A1 (en) | 2007-08-30 | 2012-04-04 | Vertex Pharmceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
| US8988881B2 (en) * | 2007-12-18 | 2015-03-24 | Sandia Corporation | Heat exchanger device and method for heat removal or transfer |
| US9005417B1 (en) | 2008-10-01 | 2015-04-14 | Sandia Corporation | Devices, systems, and methods for microscale isoelectric fractionation |
| US9795961B1 (en) | 2010-07-08 | 2017-10-24 | National Technology & Engineering Solutions Of Sandia, Llc | Devices, systems, and methods for detecting nucleic acids using sedimentation |
| US9261100B2 (en) | 2010-08-13 | 2016-02-16 | Sandia Corporation | Axial flow heat exchanger devices and methods for heat transfer using axial flow devices |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| US5353236A (en) * | 1992-04-23 | 1994-10-04 | The Board Of Trustees Of The Leland Stanford University | High-resolution crystallographic modelling of a macromolecule |
| US5453937A (en) * | 1993-04-28 | 1995-09-26 | Immunex Corporation | Method and system for protein modeling |
| IT1272179B (it) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
-
1996
- 1996-10-18 US US08/731,336 patent/US6153579A/en not_active Expired - Lifetime
-
1997
- 1997-09-12 DE DE69712085T patent/DE69712085T2/de not_active Expired - Lifetime
- 1997-09-12 ES ES01101009T patent/ES2202228T3/es not_active Expired - Lifetime
- 1997-09-12 PT PT01101009T patent/PT1118619E/pt unknown
- 1997-09-12 AT AT01101009T patent/ATE244729T1/de not_active IP Right Cessation
- 1997-09-12 AT AT03015398T patent/ATE346088T1/de not_active IP Right Cessation
- 1997-09-12 PT PT97942450T patent/PT935609E/pt unknown
- 1997-09-12 ES ES97942450T patent/ES2175462T3/es not_active Expired - Lifetime
- 1997-09-12 CA CA002264964A patent/CA2264964A1/en not_active Abandoned
- 1997-09-12 DE DE69736995T patent/DE69736995T2/de not_active Expired - Lifetime
- 1997-09-12 WO PCT/US1997/016182 patent/WO1998011134A1/en not_active Ceased
- 1997-09-12 DK DK97942450T patent/DK0935609T3/da active
- 1997-09-12 JP JP10513899A patent/JP2001501602A/ja not_active Ceased
- 1997-09-12 AT AT97942450T patent/ATE216400T1/de not_active IP Right Cessation
- 1997-09-12 DE DE69723485T patent/DE69723485T2/de not_active Expired - Lifetime
- 1997-09-12 EP EP97942450A patent/EP0935609B1/en not_active Expired - Lifetime
- 1997-09-12 IL IL12882697A patent/IL128826A0/xx unknown
- 1997-09-12 AU AU44145/97A patent/AU736857B2/en not_active Ceased
-
1999
- 1999-02-25 US US09/257,667 patent/US6303287B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6153579A (en) | 2000-11-28 |
| IL128826A0 (en) | 2000-01-31 |
| US6303287B1 (en) | 2001-10-16 |
| DK0935609T3 (da) | 2002-07-22 |
| ES2202228T3 (es) | 2004-04-01 |
| CA2264964A1 (en) | 1998-03-19 |
| JP2001501602A (ja) | 2001-02-06 |
| AU4414597A (en) | 1998-04-02 |
| WO1998011134A1 (en) | 1998-03-19 |
| DE69736995D1 (de) | 2007-01-04 |
| DE69736995T2 (de) | 2007-09-20 |
| ES2175462T3 (es) | 2002-11-16 |
| HK1038573A1 (en) | 2002-03-22 |
| EP0935609B1 (en) | 2002-04-17 |
| ATE216400T1 (de) | 2002-05-15 |
| DE69723485D1 (de) | 2003-08-14 |
| EP0935609A1 (en) | 1999-08-18 |
| AU736857B2 (en) | 2001-08-02 |
| ATE346088T1 (de) | 2006-12-15 |
| DE69712085D1 (de) | 2002-05-23 |
| HK1022700A1 (en) | 2000-08-18 |
| PT935609E (pt) | 2002-09-30 |
| ATE244729T1 (de) | 2003-07-15 |
| PT1118619E (pt) | 2003-11-28 |
| DE69723485T2 (de) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69736995T2 (de) | Kristallisierbare Zusammensetzungen, die einen Komplex von Protease-Domäne NS3 und NS4A aus dem Hepatitis C Virus enthalten, und damit bereitgestellte Kristalle | |
| CN100457776C (zh) | 丙型肝炎病毒ns5b聚合酶抑制剂结合袋 | |
| Bewley et al. | Solution structure of cyanovirin-N, a potent HIV-inactivating protein | |
| Love et al. | The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site | |
| Kim et al. | Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide | |
| Lima et al. | Three-dimensional structure of the 67K N-terminal fragment of E. coli DNA topoisomerase I | |
| Gwack et al. | DNA helicase activity of the hepatitis C virus nonstructural protein 3 | |
| DE69509504T2 (de) | Verfahrenm zum in vitro herstellung der proteolytischen wirkung von ns3 hepatitis c virus (hcv) | |
| Gallinari et al. | Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A | |
| DE602004011047T2 (de) | Kristallstruktur von der humanen coronavirus 229e hauptproteinase und deren verwendung zur entwicklung von sars-inhibitoren | |
| US20020042046A1 (en) | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex | |
| CN101851274A (zh) | 抑制丙型肝炎病毒侵入的多肽 | |
| Kang et al. | Crystallization and preliminary X-ray crystallographic analysis of the helicase domain of hepatitis C virus NS3 protein | |
| JP2001513823A (ja) | パピローマウイルス感染を阻止する化合物の構造に基づく合理的デザイン | |
| Balasco et al. | Intrinsic structural versatility of the highly conserved 412–423 epitope of the Hepatitis C Virus E2 protein | |
| EP1118619B1 (en) | Method to identify agents active against HCV by using the structure coordinates of hepatitis C virus protease | |
| EP1364961B1 (en) | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained | |
| Gesell et al. | Design, high-level expression, purification and characterization of soluble fragments of the hepatitis C virus NS3 RNA helicase suitable for NMR-based drug discovery methods and mechanistic studies | |
| Yao et al. | Application of structural biology tools in the study of viral hepatitis and the design of antiviral therapy | |
| HK1022700B (en) | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained | |
| HK1038573B (en) | Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease | |
| HK1059792A (en) | Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained | |
| US20010051333A1 (en) | Nuclear magnetic resonance methods for identifying sites in papillomavirus E2 protein | |
| Cuff | Crystal structure of a molluscan hemocyanin | |
| DE69430211T2 (de) | Ein diagnostisches antigen und verfahren zur in-vitro-diagnose einer durch den hepatitis-c-virus verursachten aktiven infektion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |